Dl-Phenylalanine

Dl-Phenylalanine

SCHEMBL1449124

NC(Cc1ccccc1)C(=O)O.c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 1.00
PTGS1 P23219 2/20 1.00
ALPI P09923 1/20 1.00
PKM P14618 1/20 1.00
XIAP P98170 1/20 1.00
SLC1A3 P43003 2/20 0.69
SLC1A2 P43004 2/20 0.69
SLC1A1 P43005 2/20 0.69
SLC15A1 P46059 1/20 0.63
CYP1A2 P05177 1/20 0.61
LTA4H P09960 1/20 0.59
GRIA2 P42262 1/20 0.59
KDM4E B2RXH2 1/20 0.58
USP2 O75604 1/20 0.58
EGFR P00533 1/20 0.58
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
ALOX15 P16050 1/20 0.58
HTR2A P28223 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Phenylalanine SCHEMBL15671104 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL16398196 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL16398197 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL385804 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL8119 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL23159186 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL43671 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL8118 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
D-Phenylalanine SCHEMBL837632 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL1331985 1.00 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10732182-B2 Method for predicting cancer sensitivity EUTROPICS PHARMACEUTICALS, INC. (US) 2020-08-04 US claimed
CN-106749461-A The vitamin B to form nanoparticle can independently be filled12Derivative and preparation method and application 暨南大学 2017-05-31 CN claimed
CN-106581645-A Drug-loaded vitamin B12 derivative self-assembled nanoparticles and preparation method and application thereof 暨南大学 2017-04-26 CN claimed
CN-1621092-A Folic acid receptor targeted liposome drug carrier and preparation method and application thereof YANG ZHENGMAO (CN) 2005-06-01 CN claimed
US-11656230-B2 Method for predicting cancer sensitivity EUTROPICS PHARMACEUTICALS, INC. (US) 2023-05-23 US disclosed
CN-113527121-B C (sp3) -C (sp2) Bond construction method and preparation method of beta-aryl amino acid 河北科技大学 2023-01-17 CN disclosed
WO-2022015974-A2 SUBSTITUTED 4-(3-AMINOPROP-1-YL)AMINOQUINOLINE ANALOGS AS MODULATORS OF MELANOMA-ASSOCIATED ANTIGEN 11 UBIQUITIN LIGASE ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) 2022-01-20 WO disclosed
CN-113527121-A C(sp3)-C(sp2)Bond construction method and preparation method of beta-aryl amino acid 河北科技大学 2021-10-22 CN disclosed
WO-2021054425-A1 BLOOD SERUM SPECIMEN INSPECTION DEVICE, AND METHOD FOR INSPECTING BLOOD SERUM SPECIMEN 伊藤 寛晃 2021-03-25 WO disclosed
US-20200393468-A1 METHOD FOR PREDICTING CANCER SENSITIVITY EUTROPICS PHARMACEUTICALS, INC. 2020-12-17 US disclosed
CN-108997575-B Polyethylene glycol-b-polytyrosine-lipoic acid copolymer, polypeptide micelle and preparation method and application thereof 苏州大学 2020-12-15 CN disclosed
CN-107998453-B Surface-modified acellular matrix and modification method thereof 中山大学附属第一医院 2020-09-25 CN disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
CN-1621092-A Folic acid receptor targeted liposome drug carrier and preparation method and application thereof YANG ZHENGMAO (CN) 2005-06-01 CN disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
EP-1109545-A4 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LTD (AU) 2004-11-10 EP disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed
EP-1109545-A1 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LTD (AU) 2001-06-27 EP disclosed
WO-2000015214-A1 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LIMITED (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 SLC7A5 176/4885PTGS1 1835/4885ALPI 2611/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A SLC7A5 4227/4885PTGS1 745/4885ALPI 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.